Joincare Pharmaceutical Group
Shenzhen-based maker of generic drugs, APIs, and OTC medicines, listed since 1993.
On the record
Checkpoint: Next earnings report expected to show whether the profit slide continues
The call
Joincare keeps the plants, approvals, and distribution that generics need, but state pricing policy is squeezing profit every quarter.
Joincare makes generic drugs and active pharmaceutical ingredients in China, selling through hospitals and pharmacies. It is hard to replace because it has 34 years of regulatory approvals, manufacturing plants certified by the government, and established relationships with hospitals, but the Chinese government's price-control policies are squeezing profit margins across the entire industry, not just Joincare. Revenue could stabilize if the government slows down price cuts, or decline further if competitors like Huadong Medicine or multinational companies like Novo Nordisk grab more market share by moving into cheaper generics as their brand-name drugs lose patent protection.
Why
01
AI pressure: None apparent. This is physical drug manufacturing under GMP rules; AI models cannot replicate plants, approvals, or distribution. Could AI do the core job? Unlikely.
02
Bigger players: Huadong Medicine. Domestic peer Huadong Medicine runs at roughly 2.7x Joincare's market cap and competes directly in generics and OTC. Could a giant copy it? Probably.
03
What protects it. Roughly 90 drug approvals, GMP-certified plants, and entrenched hospital/pharmacy distribution that new entrants cannot quickly copy.
What would change this call
Joincare's August 2026 earnings show a fifth consecutive profit decline. Would confirm VBP/NRDL margin erosion is structural, not temporary.
Regulatory approval outcome for Mapaxisave/Pixavir Marboxil influenza drug. Would show whether new product launches can offset generics pricing pressure.
Huadong Medicine's market cap gap versus Joincare widens or narrows over the next year. Would indicate whether Joincare is losing ground to its closest domestic peer.
Regulatory approval outcome for Mapaxisave/Pixavir Marboxil influenza drug. Would show whether new product launches can offset generics pricing pressure.
Huadong Medicine's market cap gap versus Joincare widens or narrows over the next year. Would indicate whether Joincare is losing ground to its closest domestic peer.
Key numbers
- Revenue fell from RMB 16.6B to 15.1B over two years
- Q3 2025 net profit down 8.61% year over year
- Q1 2026 net profit down 4.18% year over year
Named risks
- National Volume-Based Procurement and NRDL policy compresses generic drug margins sector-wide.
- Net profit has declined for four consecutive reporting periods through Q1 2026.
- Huadong Medicine and other larger domestic peers outscale Joincare in generics and API markets.
- Semaglutide patent expiry in China intensifying price competition in metabolic drug categories.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Huadong Medicine | losing to | Market cap about 2.7x Joincare's as of 2026-07-26 (CNY 50.1B vs CNY 18.4B) |
| Novo Nordisk | contesting | Semaglutide China patent expiry around March 2026 sparking obesity drug price war |
| Apeloa Pharmaceutical | contesting | Cited as comparable domestic generics and API peer by industry analysts, 2024-05-15 |
| Yabao Pharmaceutical Group | contesting | Listed as direct domestic peer in complex formulation and API space, 2024-05-15 |
Questions people ask
- Is Joincare Pharmaceutical Group profitable in 2026?
- Yes but shrinking: Joincare reported Q1 2026 net profit attributable to shareholders of RMB 406.0 million, down 4.18% year over year, per its quarterly report filed 2026-04-25, continuing a multi-quarter profit decline tied to Chinese drug pricing policy.
- Who owns Joincare Pharmaceutical Group?
- Joincare is a Shanghai Stock Exchange listed A-share company (code 600380). Its controlling shareholder, Shenzhen Baiyeyuan Investment Co., Ltd., held about 48.96% of shares as of the 2025 annual report filing dated 2026-04-01.
- Who is Joincare's biggest competitor?
- Huadong Medicine is Joincare's closest domestic generics and API peer, with a market cap around CNY 50.1 billion versus Joincare's roughly CNY 18.4 billion as of 2026-07-26, making it about 2.7 times larger by market value.
- Could AI replace Joincare's drug manufacturing business?
- Unlikely near term. Joincare's moat rests on physical GMP-certified plants and roughly 90 marketed drug regulatory approvals plus entrenched hospital and pharmacy distribution, none replicable by AI. Only formulation screening and marketing content are AI exposed, per company statements from 2025-04-07.
- Is Joincare's revenue growing or shrinking?
- Shrinking. Revenue dropped from RMB 16.646 billion in FY2023 to RMB 15.619 billion in FY2024 and RMB 15.088 billion in FY2025, a 2.60% year over year decline per Joincare's own 2025 annual report filed 2026-04-01, driven by national drug price controls.
- Does Joincare Pharmaceutical Group trade outside China?
- Yes. Alongside its Shanghai A-share listing (600380), Joincare listed Global Depositary Receipts under ticker JCARE on SIX Swiss Exchange and Deutsche Börse in September 2022, raising roughly USD 92.0 million in gross proceeds, per a 2022-09-26 SIX Group release.
Timeline
- 2026-04-25Q1 2026 report: net profit RMB 406.0 million, down 4.18% year over year
- 2026-04-012025 Annual Report filed: revenue RMB 15.088 billion, down 2.60% year over year
- 2026-01-13SCMP reports China obesity drug price war intensifying ahead of semaglutide patent expiry
- 2025-12-05Livzon subsidiary renews continuing connected transaction agreements with Joincare group
- 2025-10-24Q3 2025 report: quarterly net profit down 8.61% year over year, nine month profit down 1.83%
- 2025-05-08LivzonBio capital restructuring brings in outside investor YF Pharmab, about RMB 1 billion raised
- 2025-04-07Company touts FY2024 net profit of RMB 1.387 billion and internal AI upgrade initiative
- 2025-03-26Livzon announces LivzonBio equity stake adjustment, Joincare stake reduced to 22.58%
- 2023-11Joincare acquires rights to anti-TSLP monoclonal antibody for asthma and COPD
- 2022-09-26Joincare lists GDRs on SIX Swiss Exchange and Deutsche Börse, raising about USD 92.0 million
Revision history
26 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources